Prospective Registry of Patients With Isolated Severe Tricuspid Regurgitation
NCT ID: NCT01502462
Last Updated: 2021-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
131 participants
OBSERVATIONAL
2012-02-29
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim: To evaluate clinical course and prognostic factors of patients with severe isolated TR.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patients With Severe TrIcuspid Regurgitation After triCvALve System Implantation
NCT05820516
Risk Stratification in Severe Treatment-naive, Tricuspid Regurgitation
NCT04173091
Application of Comprehensive Non-invasive Assessment To Phenotype Tricuspid Regurgitation
NCT07042360
Minimally Invasive Tricuspid Surgery vs Medical Treatment for Severe TR
NCT04339192
Characteristics and Prognosis of Moderate or Severe Tricuspid Regurgitation
NCT03546231
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Exclusion criteria
1. Severe mitral and aortic valvular heart disease
2. Age equals to or more than 75 years
3. Malignancy or serious comorbidity with life expectancy \< 5years
4. Acute or subacute infective endocarditis requiring antibiotics therapy
5. Untreated hyperthyroidism
6. Constrictive pericarditis
7. Unclosed significant atrial septal defect
8. Previous tricuspid valve surgery
9. Significant coronary artery disease
10. Cardiomyopathy
11. Pregnancy
12. Severe resting pulmonary hypertension(TR Vmax \>4.0 m/s)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Age equals to or more than 75 years
3. Malignancy or serious comorbidity with life expectancy \< 5years
4. Acute or subacute infective endocarditis requiring antibiotics therapy
5. Untreated hyperthyroidism
6. Constrictive pericarditis
7. Unclosed significant atrial septal defect
8. Previous tricuspid valve surgery
9. Significant coronary artery disease
10. Cardiomyopathy
11. Pregnancy
12. Severe resting pulmonary hypertension(TR Vmax \>4.0 m/s)
16 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jong-Min Song
Associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Severe_Isol_TR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.